Price Don’t Lie: What’s Cipher Pharmaceuticals Inc Downside After Achieving Yearly Low?

Price Don't Lie: What's Cipher Pharmaceuticals Inc Downside After Achieving Yearly Low?

The stock of Cipher Pharmaceuticals Inc (NASDAQ:CPHR) hit a new 52-week low and has $2.37 target or 11.00% below today’s $2.66 share price. The 5 months bearish chart indicates high risk for the $76.51M company. The 1-year low was reported on Nov, 14 by If the $2.37 price target is reached, the company will be worth $8.42M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 16,290 shares traded hands or 177.75% up from the average. Cipher Pharmaceuticals Inc (NASDAQ:CPHR) has declined 51.17% since April 12, 2016 and is downtrending. It has underperformed by 56.15% the S&P500.

Cipher Pharmaceuticals Inc (NASDAQ:CPHR) Ratings Coverage

Out of 2 analysts covering Cipher Pharma (NASDAQ:CPHR), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cipher Pharma has been the topic of 2 analyst reports since November 30, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Monday, November 30 by CBIC. IBC initiated Cipher Pharmaceuticals Inc (NASDAQ:CPHR) on Monday, November 30 with “Sector Outperform” rating.

According to Zacks Investment Research, “Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company. It develops improved formulations of existing drugs. The Company’s core capabilities include clinical and regulatory affairs, product licensing, supply chain management, and marketing and sales. It has three commercial products and a fourth in development. The Company’s products include a fenofibrate formulation marketed in the United States as Lipofen (R); an extended-release tramadol, which is marketed in the United States as ConZip (R) and in Canada as Durela (R); and a novel formulation of the acne treatment isotretinoin, which is marketed in the United States as Absorica (TM) and in Canada as Epuris (R). Cipher Pharmaceuticals Inc. is based in Mississauga, Canada.”

More notable recent Cipher Pharmaceuticals Inc (NASDAQ:CPHR) news were published by: which released: “Cipher Pharmaceuticals Inc. Announces Changes to its Board of Directors” on August 09, 2016, also with their article: “Cipher Pharmaceuticals Inc. announces Sitavigâ„¢ accepted for review by Health …” published on February 16, 2016, published: “Cipher Pharmaceuticals acquires assets of Melanovus Oncology Inc.” on January 09, 2015. More interesting news about Cipher Pharmaceuticals Inc (NASDAQ:CPHR) were released by: and their article: “Cipher Pharmaceuticals announces U.S. commercial entry through acquisition of …” published on April 13, 2015 as well as‘s news article titled: “Cipher Pharmaceuticals Appoints Ralph Bohrer President & General Manager of US …” with publication date: March 04, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment